Optimizing Outcomes in HR+/HER2-Metastatic Breast Cancer: Molecular Testing and Targeted Strategies

Optimizing Outcomes in HR+/HER2-Metastatic Breast Cancer: Molecular Testing and Targeted Strategies

Episodes

Specialty:

All

Year:

All

EP. 1: Clinical Perspectives on Biomarker Testing in mBC

ByJoyce O’Shaughnessy, MD,Alison Conlin, MD

March 6th 2025

EP. 2: Repeat Biomarker Testing in mBC: Navigating the Rapidly Evolving Treatment Landscape

ByJoyce O’Shaughnessy, MD,Alison Conlin, MD

March 6th 2025

EP. 3: Selecting the Optimal CDK4/6 Regimen for First-Line Therapy

ByJoyce O’Shaughnessy, MD,Alison Conlin, MD

March 6th 2025

EP. 4: Clinical Considerations for CDK4/6 Inhibition Beyond Progression

ByJoyce O’Shaughnessy, MD,Alison Conlin, MD

March 6th 2025

EP. 5: Expert Insights: Managing Patients with PIK3CA Mutations

ByJoyce O’Shaughnessy, MD,Alison Conlin, MD

March 6th 2025

EP. 6: Navigating Treatment Selection in Patients with Both ESR1 and PIK3CA Mutations and Expert Perspective for Integrating Oral SERDs into Clinical Practice

ByJoyce O’Shaughnessy, MD,Alison Conlin, MD

March 6th 2025

EP. 7: The Emerging Role of Triplet Therapy in mBC: Opportunities and Challenges

ByJoyce O’Shaughnessy, MD,Alison Conlin, MD

March 6th 2025

EP. 8: The Evolving Landscape of mBC Treatment: Unmet Needs and Future Predictions

ByJoyce O’Shaughnessy, MD,Alison Conlin, MD

March 6th 2025

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management

B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer

Selecting Frontline Therapy for High-Risk EGFR-Mutated NSCLC

The OncFive: Top Oncology Articles for the Week of 8/30